Skip to content

ULTIMEDI

Active
Private limited companyfounded 2011active for 15 yearsFlandria 5, 8750 Wingene, BelgiumKBO/BCE: BE 0834.340.946
Summary

ULTIMEDI has been active since 2011 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €1.9m and a net result of -€141,203. Equity is growing by about 12% per year across the filed financial years. Its solvency ranks better than 30% of 6,071 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.5% (low).

Overview

Activity
Wholesale of pharmaceutical and medical goods
NACE 46460
#8 company by staff growth in Wingene1 site
Size
€11.3mturnover 2025
Staff
18.4 FTE
Equity
€1.9m
Loss
-€141,203
Turnover +139%: 12-month year
Financial health
79 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.5%
Structure
Parent
Bobbie Pharmaceutical Services · 100%
Auditor: FIGURAD BEDRIJFSREVISORENAccounts 11 days early1 of 8 deeds read
Why 79raises riskLiquidity: current ratio 1.51, cash €42,088, halvedLoss of €141,203 (financial year 2025)lowers riskFounded in 2011Figures for financial year 2025 (filed 20-07-2026)Show the evidence

Checked score

Score 2025
79 / 100
Excellent
Probability in this band: under 0.55%
Financially better than 29% of its sector peers (NACE 46, small)
Financial strength · tick = 2024
Weak
Solvency 52-26
equity 27.2% of total assets
Liquidity 19-24
short-term debt 60.8% · cash 0.6%
Profitability 16-56
return on assets -2.0%
Bankruptcy probability, 12 months
0.5% Low
0%0.5%1.5%4%10%≥ 25%

About 5 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.2% (4,382 companies, NACE 46, small)
Last 24 months 11-2024: < 0.1%lowest value 12-2024: 0.1%▲ +0.1 percentage points vs 11-2024 01-2025: 0.1%● unchanged vs 12-2024 02-2025: 0.1%● unchanged vs 01-2025 03-2025: 0.1%● unchanged vs 02-2025 04-2025: 0.1%● unchanged vs 03-2025 05-2025: 0.1%● unchanged vs 04-2025 06-2025: 0.1%● unchanged vs 05-2025 07-2025: 0.1%● unchanged vs 06-2025 08-2025: 0.1%● unchanged vs 07-2025 09-2025: 0.1%● unchanged vs 08-2025 10-2025: 0.1%● unchanged vs 09-2025 11-2025: 0.1%● unchanged vs 10-2025 12-2025: 0.1%● unchanged vs 11-2025 01-2026: 0.1%● unchanged vs 12-2025 02-2026: 0.1%● unchanged vs 01-2026 03-2026: 0.2%▲ +0.1 percentage points vs 02-2026 04-2026: 0.2%● unchanged vs 03-2026 05-2026: 0.2%● unchanged vs 04-2026 06-2026: 0.2%● unchanged vs 05-2026 07-2026: 0.2%● unchanged vs 06-2026 08-2026: 0.6%▲ +0.4 percentage points vs 07-2026highest value 09-2026: 0.6%● unchanged vs 08-2026highest value 10-2026: 0.5%▼ -0.1 percentage points vs 09-2026
Credit of up to €150,000 on 30-day terms is acceptable
Liquidity ample (current ratio 1.51, compared with 3.29 in 2024; short-term debt: 60.8% and cash: 0.6% of total assets), but 72.8% of the assets are financed with debt.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, small): better than 31% on solvency, 16% on liquidity, 10% on profitability and 60% on growth.

The bankruptcy probability was computed on 09-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.
−lowers risk+raises risk○neutral
raises risk · Liquidity: current ratio 1.51, cash €42,088, halved
NBB · annual accounts
lowers risk · Founded in 2011
How long the company has existed counts in the probability; how much depends on the rest of its profile.
KBO
raises risk · Loss of €141,203 (financial year 2025)
NBB · annual accounts
lowers risk · Figures for financial year 2025 (filed 20-07-2026)
NBB · annual accounts
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 20-07-2026, 11 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
11 days early
2024
21 days early
2024
1 day early
2023
on the day
2022
1 day early
2021
on the day
2020
2 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 5 days before the deadline; the sector median (NACE 46) for financial year 2024 is 3 days before the deadline, and 39% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven months
Where today falls in the filing period
09-10-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage
  1. Annual accounts filedfinancial year 2025 · full…
  2. Weakest financial yearnet -€141,203
  3. Reappointment: BV FIGURAD BEDRIJFSREVISOREN (statutory auditor)Permanent representative: Geoffrey Loontjes

Key points

  • Caution: From profit to loss in 2025after €330,890 in 2024 -€141,203 View
  • Caution: Among the weakest 12% on net resultsector median €113,257 · 6,012 companies -€141,203 View
  • Positive: Filed on time since financial year 2019accounts within the deadline every year 8 years View
  • Controlled by Bobbie Pharmaceutical Services 100% View

By topic

Financials

Financial year
2025
Turnover
€11.3m
Loss
-€141,203
Solvency
27.2%
Turnover▲ 139%
Net result
20242025
Go to Financials

Board & ownership

Parent
Bobbie Pharmaceutical Services · 100%
Auditor
FIGURAD BEDRIJFSREVISOREN
Go to Board & ownership

Timeline

Events
22
Since
2013
Next accounts
by 31-07-2027
  1. 10-07-2025Annual accounts filed
  2. 30-01-2025Annual accounts filed
  3. 31-12-2024Equity above €2m
Go to Timeline

Company details

Sites
1
Legal form
Private limited company
Activity
Wholesale of pharmaceutical and medical goodsNACE 46460
Founded
04-03-2011
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Go further with this company

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.